Roorkee Raid Uncovers Illicit Drug Stockpile: Authorities Seize Medicines Meant for Rajasthan, MP Government Schemes

Roorkee In a startling expose of supply chain corruption, the Uttarakhand Drug Department’s enforcement team raided an unlicensed medical outlet in Roorkee, seizing a massive cache of illegal allopathic medicines—including stocks stamped for free distribution in Rajasthan and Madhya Pradesh government health programs—highlighting a brazen diversion racket feeding unregistered practitioners and the black market.
The operation targeted M/s Falak Naz, a nondescript establishment in Village Saliyar, Roorkee, following a tip-off about its unlicensed operations supplying drugs to quack doctors in the region. Led by Senior Drug Inspector Anita Bharti, along with Inspectors Harish Singh and Megha, the team descended on the site on October 14, conducting a thorough inspection that uncovered no valid drug license or purchase-sale records from the operator, who was interrogated on the spot. Under the glare of witnesses, officials drafted a seizure memo (Form-16) and spot memo, meticulously packing and sealing the contraband to prevent tampering.
Among the haul were large quantities of various allopathic formulations, including at least 12 specific types earmarked exclusively for government hospitals and health centers in Rajasthan and Madhya Pradesh. These included essential antibiotics, analgesics, and pediatric syrups—intended for gratis distribution under state welfare schemes—now illicitly repackaged for private sale. The discovery has ignited alarms over systemic pilferage, with preliminary probes suggesting the medicines were siphoned from official channels and funneled to over a dozen unregistered “jhola-chhap” (quack) doctors in nearby villages, endangering public health amid Uttarakhand’s rising cases of antibiotic resistance.
No arrests were made during the raid, but the unnamed operator faces immediate legal repercussions under the Drugs and Cosmetics Act, 1940, with potential penalties including fines up to ₹5 lakh and imprisonment for up to five years for unlicensed trade and adulteration risks. The department has launched a deeper investigation into the procurement trail, vowing to trace upstream suppliers and accomplices. “This case is extremely serious because government-supplied medicines are usually for free distribution. Their presence in the private market indicates a larger network,” Bharti stated, adding that a thorough probe will unearth how these stocks escaped official oversight and identify all involved parties.
Drug Inspector Harish Singh echoed the gravity, noting: “Preliminary investigation indicates that such medicines were being supplied to several quack doctors in surrounding areas.” Officials suspect links to interstate syndicates, especially given the recent nationwide crackdown on counterfeit and diverted pharmaceuticals, including toxic cough syrup scandals in Madhya Pradesh and Chhattarakhand. The seized items, pending lab verification for quality and expiry, could reveal further adulteration, prompting calls for enhanced tracking via the CDSCO’s digital portals.
This bust underscores persistent vulnerabilities in India’s ₹2 lakh crore pharma sector, where diversion of subsidized drugs costs the exchequer billions annually and fuels unsafe practices by unqualified healers. The Uttarakhand Health Department has alerted counterparts in Rajasthan and Madhya Pradesh for collaborative inquiries, while urging the public to verify prescriptions through licensed chemists and report suspicious outlets via the toll-free helpline 1800-180-4001. As festive season demand surges, experts warn that such rackets not only erode trust in healthcare but pose lethal risks, reminiscent of the 2023 global syrup contamination crises. The operator’s premises remain sealed pending court orders, with the SIT-like probe expected to yield more revelations soon.

Related Posts

India’s Pharma Sector Must Expand AI Use Beyond R&D: Reports

The report emphasizes that absolute R&D spending remains modest and identifies expanding investment in advanced biologics and AI-driven drug discovery as the “largest opportunity” for bridging the innovation divide. Recent…

India’s Pharma, Healthcare Funding Hits $38.6 Mn in Nov’25

Early-stage activity drove the month, accounting for 73.6 per cent of total investments, while seed-stage rounds contributed the remaining 26.4 per cent. India’s pharma and healthcare funding for November 2025…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

India’s Pharma Sector Must Expand AI Use Beyond R&D: Reports

India’s Pharma Sector Must Expand AI Use Beyond R&D: Reports

India headed for Culture of ‘Divya Buildings’, thanks to AMTZ’s Landmark Initiative

India headed for Culture of ‘Divya Buildings’, thanks to AMTZ’s Landmark Initiative

India’s Pharma, Healthcare Funding Hits $38.6 Mn in Nov’25

India’s Pharma, Healthcare Funding Hits $38.6 Mn in Nov’25

Novo Nordisk gears up for December Ozempic launch

Novo Nordisk gears up for December Ozempic launch

Illegal intoxicant tablets seized in large quantity from Sirsa medical store, two held

Illegal intoxicant tablets seized in large quantity from Sirsa medical store, two held

Higher pharma, chemicals exports to Russia bloc on agenda to trim deficit

Higher pharma, chemicals exports to Russia bloc on agenda to trim deficit